Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial

Arabi, YM; Gordon, AC; Derde, LPG; Nichol, AD; Murthy, S; Beidh, FA; Annane, D; Swaidan, LA; Beane, A; Beasley, R; Berry, LR; Bhimani, Z; Bonten, MJM; Bradbury, CA; Brunkhorst, FM; Buxton, M; Buzgau, A; Cheng, A; De Jong, M; Detry, MA; Duffy, EJ; Estcourt, LJ; Fitzgerald, M; Fowler, R; Girard, TD; Goligher, EC; Goossens, H; Haniffa, R; Higgins, AM; Hills, TE; Horvat, CM; Huang, DT; King, AJ; Lamontagne, F; Lawler, PR; Lewis, R; Linstrum, K; Litton, E; Lorenzi, E; Malakouti, S; McAuley, DF; McGlothlin, A; Mcguinness, S; McVerry, BJ; Montgomery, SK; Morpeth, SC; Mouncey, PR; Orr, K; Parke, R; Parker, JC; Patanwala, AE; Rowan, KM; Santos, MS; Saunders, CT; Seymour, CW; Shankar-Hari, M; Tong, SYC; Turgeon, AF; Turner, AM; Van de Veerdonk, FL; Zarychanski, R; Green, C; Berry, S; Marshall, JC; McArthur, C; Angus, DC; Webb, SA; Orford, Neil

1/1

2 files

Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial

Version 2 2024-06-04, 07:46

Version 1 2021-10-04, 22:22

journal contribution

posted on 2024-06-04, 07:46 authored by YM Arabi, AC Gordon, LPG Derde, AD Nichol, S Murthy, FA Beidh, D Annane, LA Swaidan, A Beane, R Beasley, LR Berry, Z Bhimani, MJM Bonten, CA Bradbury, FM Brunkhorst, M Buxton, A Buzgau, A Cheng, M De Jong, MA Detry, EJ Duffy, LJ Estcourt, M Fitzgerald, R Fowler, TD Girard, EC Goligher, H Goossens, R Haniffa, AM Higgins, TE Hills, CM Horvat, DT Huang, AJ King, F Lamontagne, PR Lawler, R Lewis, K Linstrum, E Litton, E Lorenzi, S Malakouti, DF McAuley, A McGlothlin, S Mcguinness, BJ McVerry, SK Montgomery, SC Morpeth, PR Mouncey, K Orr, R Parke, JC Parker, AE Patanwala, KM Rowan, MS Santos, CT Saunders, CW Seymour, M Shankar-Hari, SYC Tong, AF Turgeon, AM Turner, FL Van de Veerdonk, R Zarychanski, C Green, S Berry, JC Marshall, C McArthur, DC Angus, SA Webb, Neil OrfordNeil Orford

Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial

History

Journal

Intensive Care Medicine

Volume

47

Pagination

867-886

Location

Heidelberg, Germany

Publisher DOI

https://doi.org/10.1007/s00134-021-06448-5

Open access

Yes

Link to full text

https://link.springer.com/content/pdf/10.1007/s00134-021-06448-5.pdf

ISSN

0342-4642

eISSN

1432-1238

Language

eng

Publication classification

C1 Refereed article in a scholarly journal

Publisher

Springer

Usage metrics

Keywords

3202 Clinical sciences 3214 Pharmacology and pharmaceutical sciences

Licence

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial

History

Journal

Volume

Pagination

Location

Publisher DOI

Open access

Link to full text

ISSN

eISSN

Language

Publication classification

Publisher

Usage metrics

Categories

Keywords

Licence

Exports